Hemanext Expands Board of Directors with Two New Members
Lexington, PA May 05, 2025 --( PR.com )-- Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces the appointment of two distinguished professionals to its Board of Directors. Joe Grogan and Phil Pead join the visionary leaders that are steering Hemanext's path to improving the standard of care for patients who rely on transfusions.
Joe Grogan is a healthcare expert with over two decades of experience in both the private sector and government, particularly in Washington, DC. He began his career as Executive Director of the Presidential Advisory Council on HIV and AIDS during the George W. Bush administration and later worked at the Food and Drug Administration (FDA). In the private sector, he advised Wall Street investors and worked for Amgen and Gilead Sciences, where he founded Gilead's DC office and led federal efforts during three major drug launches. Joe also served at the Office of Management and Budget, managing over $1.3 trillion in healthcare spending and drafting health sections of three Presidential Budgets. He later served as Domestic Policy Advisor in the West Wing, leading healthcare policy development and contributing to the President's Covid Task Force. Joe founded Fire Arrow to guide innovators through the complexities of Washington, DC, and help deliver products to those in need.
Phil M Pead is a seasoned technology executive and board member with over 40 years of leadership experience in the Healthcare IT and software industries. He has served as CEO of Per-Se Technologies, Eclipsys, and Progress Software, leading major turnarounds, mergers, and acquisitions. He currently sits on the boards of Modernizing Medicine and WebPT and has held past roles with Change Healthcare and Allscripts. A Harvard Business Review case study highlights his leadership at Per-Se, and he has taught the 'Managing in Adversity' class at MIT Sloan Business School for four years. He is also a national board member and Secretary for the Posse Foundation.
Andrew Dunham, CEO of Hemanext, warmly welcomes the addition to Hemanext's Board of Directors, 'We're thrilled to welcome Joe and Phil to our Board of Directors. Their expertise and vision will be invaluable as we continue to grow and innovate. We're excited for the journey ahead with such strong additions to our leadership team.'
About Hemanext
Hemanext is a privately held medical technology company based in Lexington, MA, that is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company's research and development efforts focus on the study of hypoxically stored Red Blood Cells (RBCs). The company's aim is to significantly improve the quality of stored RBCs worldwide.
Visit Hemanext.com to learn more about the Company.
About Hemanext ONE
Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration. It is intended to process and store CP2D/AS-3 Red Blood Cells, Leukocytes Reduced (LR RBC) that have been prepared within the standard 8-hour hold time. Processing of Red Blood Cells processed with the Hemanext ONE system must be initiated within 8 hours of collection and completed within 12 hours of collection. The Red Blood Cells must be processed at room temperature (20-26°C). The Hemanext ONE system limits O2 and CO2 levels in the storage environment. Red Blood Cells Leukocytes Reduced, O2/ CO2 Reduced may be stored for up to 42 days at 1-6°C. Hemanext ONE is used for volumes no greater than 350 mL of LR RBC.
In Europe, Hemanext ONE is CE marked, which allows its commercial distribution within the market of the European Economic Area (EEA).
The Hemanext ONE RBC Processing and Storage system limits oxygen, the fuel for oxidative damage, providing a higher quality blood product (1,2,3). It has the potential to benefit all patients requiring transfusion for chronic conditions, such as thalassemia (4), sickle cell disease (SCD) (5), and myelodysplastic syndromes (MDS) (6), as well as those in need of critical transfusions during acute bleeding in surgery, trauma and other medical procedures (7).
Hemanext ONE creates hypoxic RBCs, RBCs that have been processed to reduce oxygen and carbon dioxide content of RBCs and to maintain these levels throughout storage up to 42 days (3). Hypoxic RBCs have demonstrated positive impacts on multiple in vitro metrics of RBC quality in preclinical studies (8,9). Clinical studies are underway to determine the impact of hypoxic RBCs on patient outcomes and estimate potential cost savings from expected improvements in care and reductions in transfusion volumes (10).
Hemanext Media Contact
Robert Haime
Vice President, Commercial
[email protected]
(781) 301-7474
References
1. Rabcuka J, Blonski S, Meli A, et al. Metabolic reprogramming under hypoxic storage preserves faster oxygen unloading from stored red blood cells. Blood Adv. 2022;6(18):5415-5428. doi: 10.1182/bloodadvances.2022007774
2. Reisz JA, Wither MJ et al. Oxidative modifications of glyceraldehyde 3-phosphate dehydrogenase regulate metabolic reprogramming of stored red blood cells. 2016;128(12): e32-42.
3. Hemanext ONE® (Blood container set used to process and store CP2D/AS-3 Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced) [US Instructions for Use]. Lexington, MA: Hemanext Inc.
4. Farmakis D, Porter J, Taher A, et al. 2021 Thalassemia International Federation Guidelines for the management of transfusion-dependent thalassemia. 2022;6:8.
5. Chou S, Alsawas M, Fasano R, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4:2.
6. Germing U, Oliva E, Hiwase D, and Almeida A. Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies. 2019;3(6). doi: 10.1097/HS9.0000000000000314
7. American College of Surgeons. ACS TQIP massive transfusion in trauma guidelines. ACS TQIP. 2014; https://www.facs.org/media/zcjdtrd1/transfusion_guildelines.pdf.
8. Yoshida T, Blair A, D'Alessandro A, et al. Enhancing uniformity and overall quality of red cell concentrate with anaerobic storage. Blood Transfus. 2017;15(2):172-81.
9. Yoshida T, McMahon E, Croxon H, et al. The oxygen saturation of red blood cell concentrates: The basis for a novel index of red cell oxidative stress. Transfusion. 2022;62(1):183-193. doi: 10.1111/trf.16715.
10. Reikvam H, Hetland G, Ezligini F, et al. Safety of hypoxic red blood cell administration in patients with transfusion-dependent hematological malignancies: An interim analysis. Transfus Apher Sci. 2023; doi: 10.1016/j.transci.2023.103755.
Contact Information:
Hemanext
Robert Haime, Vice President, Commercial
(781) 301-7474
Contact via Email
https://hemanext.com
Read the full story here: Hemanext Expands Board of Directors with Two New Members
Press Release Distributed by PR.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression
- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo's CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104 (liafensine) in treatment-resistant depression (TRD) - SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative drugs, today announced the formation of its neuroscience-focused Scientific Advisory Board (SAB) comprised of distinguished experts in the field. The SAB will be chaired by Charles B. Nemeroff, M.D., Ph.D., Chair and Professor of the Department of Psychiatry and Behavioral Sciences at Dell Medical School at The University of Texas at Austin. Dr. Nemeroff served as president of the American College of Psychiatrists and the American College of Neuropsychopharmacology, and is past-president of the Anxiety and Depression Association of America (ADAA). 'We are extremely honored to welcome such a distinguished group of scientific leaders to join our efforts at Denovo Biopharma as we work towards addressing a major unmet need in the psychiatry field with a novel precision medicine,' said Wen Luo, Ph.D., Chief Executive Officer of Denovo Biopharma. 'As we prepare our lead asset, DB104, to enter a biomarker-guided Phase 3 study in TRD, we believe their guidance will be instrumental in shaping both our clinical development strategy and our regulatory path forward. We are thankful for their support and look forward to collaborating as we work to advance a first-in-class, potentially transformative therapy for patients with TRD.' Other members of Denovo's neuroscience Scientific Advisory Board include: Stephen Brannan, M.D., is a neuroscience drug development expert with over 15 years of industry experience. He most recently served as Chief Medical Officer at Karuna Therapeutics, where he was instrumental in the development of CobenfyTM for the treatment of schizophrenia, which was later acquired by Bristol Myers Squibb for $14 billion. Prior to Karuna, Dr. Brannan was the Therapeutic Head of Neuroscience at Takeda and Vice President for Clinical Research and Medical Affairs at Forum Pharmaceuticals. Dr. Brannan has been active in the development of multiple important central nervous system treatments including Cymbalta®, Exelon Patch®, Trintellix®, and Vagal Nerve Stimulation for TRD during his tenures at Forum, Takeda, Novartis, Cyberonics, and Eli Lilly. Sanjay Mathew, M.D., is Professor of Psychiatry and Behavioral Sciences, Director of Mood and Anxiety Disorders Program, and Vice Chair for Research at Baylor College of Medicine. He is currently ADAA's President-Elect and Chief Medical Officer. Dr. Mathew is a leading expert in the areas of experimental therapeutics and pathophysiology of TRD, suicide, and PTSD. About DB104 (biomarker-guided liafensine) Liafensine is a first-in-class triple reuptake inhibitor targeting transporters for serotonin, norepinephrine, and dopamine. It was licensed from Albany Molecular Research, Inc. (now Curia) and was previously developed by Bristol-Myers Squibb (BMS), who had conducted two large Phase 2b clinical trials in non-selected TRD patient population. Denovo's unique artificial intelligence (AI) and whole genome sequencing (WGS)-based Denovo Genomic Marker (DGM™) biomarker platform allowed discovery of a novel genetic biomarker at the ANK3 gene, with a strong correlation of ANK3-positive status with liafensine's efficacy in the BMS studies. Denovo's ENLIGHTEN Phase 2b study results prospectively demonstrated the use of ANK3 as a predictive biomarker for liafensine's efficacy in TRD patients, a first for genetic biomarkers in psychiatry. About Denovo Biopharma Denovo Biopharma LLC is a clinical-stage biopharmaceutical company that uses novel biomarker approaches to execute efficient clinical trials in targeted patient subpopulations to increase the probability of success. Denovo has seven late-stage drugs in its pipeline addressing major unmet medical needs in central nervous system diseases and oncology, most of which are first in class drugs with global rights. Visit for additional information. Investor Contact: Stephen Jasper Gilmartin Group stephen@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Tom's Guide
5 days ago
- Tom's Guide
3 new to Prime Video movies with 90% or higher on Rotten Tomatoes
We're somehow in June already, and Prime Video is rolling out another batch of movie titles to sink your teeth into. As always, the streaming service's library is packed with a mix of classics, recent hits and a few hidden gems. But if you're someone who likes to let the critics do some of the legwork, it's worth narrowing your search by looking at what's earned top marks. While there's no shortage of well-reviewed movies in this month's lineup, only a handful actually crossed that elusive 90% threshold on Rotten Tomatoes — a mark that signals near-universal praise and a strong bet for your next movie night. The three picks below all cleared that bar and are now available to stream. Here are the most critically acclaimed new additions to Prime Video in June 2025. We're starting off with an absolute classic. '12 Angry Men' is a courtroom drama about a jury deliberating the fate of a teenage boy accused of murdering his father. The entire movie takes place almost entirely in one room, where 12 jurors must come to a unanimous verdict. At first, nearly all of them are convinced the boy is guilty. But one juror (Henry Fonda) has doubts and refuses to convict without discussing the evidence more thoroughly. As tensions rise and personalities clash, the jurors are forced to confront their own biases, assumptions, and the concept of reasonable doubt. It's a gripping, dialogue-driven movie about justice and the importance of standing up for what's right, even when you're the only one doing it. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. Rotten Tomatoes score: 100%Stream it on Prime Video now 'Moneyball' is based on the true story of Billy Beane, the general manager of the Oakland A's baseball team, and his revolutionary approach to building a competitive team on a limited budget. Faced with losing his star players and unable to afford big-name replacements, Beane (Brad Pitt) teams up with a young Yale economics graduate, Peter Brand (Jonah Hill), to challenge traditional scouting methods. They use data-driven analysis known as sabermetrics to identify undervalued players who can still deliver results. The movie isn't just about baseball but about challenging the status quo and finding value where others don't. 'Moneyball' is as much about heart and strategy as it is about the game itself. Rotten Tomatoes score: 94%Stream it on Prime Video now 'Some Like It Hot' is a classic screwball comedy about two down-on-their-luck musicians who witness a mob hit and go on the run by disguising themselves as women and joining an all-female band. Tony Curtis and Jack Lemmon play Joe and Jerry, who become 'Josephine' and 'Daphne' to hide from the gangsters chasing them. On the road with the band, they meet the charming and naive Sugar Kane (played by Marilyn Monroe), a ukulele player with a troubled romantic past. Complications ensue as Joe falls for Sugar while pretending to be a woman, and Jerry unexpectedly finds himself being courted by a wealthy older man. 'Some Like It Hot' is actually widely regarded as one of the greatest comedies of all time. Rotten Tomatoes score: 95%Stream it on Prime Video now
Yahoo
5 days ago
- Yahoo
I make over $100K with a great pension — but I dread going into work every day. Should I quit or stick it out?
For almost a decade, Joe has worked for the county, pulling in an enviable salary of more than $100K a year. Not only does he have job security, but he also gets generous vacation time, health insurance and a pension. His friends and family think he's got it made. But every morning, Joe dreads going to work. He doesn't get along with his overbearing manager, and the work environment has turned toxic. On top of that, he's bored. The job is repetitive, and there's no room to grow within the department. Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how I'm 49 years old and have nothing saved for retirement — what should I do? Don't panic. Here are 5 of the easiest ways you can catch up (and fast) Nervous about the stock market in 2025? Find out how you can access this $1B private real estate fund (with as little as $10) To get his full pension, Joe still has 30 years of work ahead of him. He can't imagine staying in a job he hates for three more decades — but he also wonders if the money and benefits are too good to walk away from. Joe isn't alone. Worker engagement hit an 11-year low in early 2024, with only 30% of full- and part-time American employees saying they felt highly engaged at work, according to Gallup's long-running workplace poll. So why do they stay? One reason is golden handcuffs — benefits or incentives that make it financially attractive to stick around. That includes pensions, bonuses, stock options and even company cars. Often, you have to stay with an employer for a certain period before you're eligible for those benefits, which can make some employees feel trapped, especially when they're already unhappy. Here are a few tips to help you financially plan an exit from a high-paying but soul-draining job. Start by calculating your bare-bones budget — the minimum you need to cover essential expenses like housing, utilities, bills, insurance, transportation, healthcare and groceries. Don't forget minimum debt payments and regular savings, such as contributions to retirement. Once you add it all up, you'll have your survival number — the amount you need to earn to meet basic living expenses. That number could help Joe figure out whether a low-paying but more fulfilling job could support his lifestyle. With your survival number in hand, you can take a hard look at your current spending. That means combing through your bank and credit card statements, digital transactions and savings activity. Where can you cut back? Maybe it's canceling subscriptions or limiting takeout. Or maybe you need to delay a bigger purchase like a new car or home renovation. If your housing costs are eating up more than 30% of your gross monthly income — the standard threshold for affordability — could you downsize or take on a roommate? It might make sense to make those changes before leaving the job you hate. Read more: Want an extra $1,300,000 when you retire? Dave Ramsey says — and that 'anyone' can do it Use free online pension calculators to estimate what you might receive based on your current salary, years of service and retirement age. Try running scenarios: What would your pension look like if you stayed another five, 10, 20 or 30 years? Many county pension plans allow you to collect a pension even if you leave before retirement age, provided you've met the service requirements. Some plans let you transfer your benefits to a new employer's plan or withdraw your contributions in a lump sum. You can run these numbers yourself or work with a financial advisor to explore what would happen if you invested those funds on your own. You might find that managing your own retirement plan could leave you just as well off. Every pension plan is different, so talk to your pension plan administrator before making any big moves. Even if you're ready to leave, it's smart to develop an exit strategy. Give yourself time to build a quit fund and line up your next opportunity. Start networking, reach out to recruiters and apply to jobs. Depending on your qualifications and industry, it could take a while to find the right fit — but laying the groundwork now makes the transition easier. Leaving a new job lined up can be challenging, so aim to build a quit fund that covers 6 to 12 months of living expenses. Keep it separate from retirement savings and in a highly liquid account — like a high-yield savings account — in case you need it. Joe could also look into whether his skills are transferable to another county department or whether upskilling could help him move up. That way, he might be able to escape his toxic manager and find more fulfilling work — without giving up benefits and pension. Here are 5 'must have' items that Americans (almost) always overpay for — and very quickly regret. How many are hurting you? Rich, young Americans are ditching the stormy stock market — here are the alternative assets they're banking on instead Robert Kiyosaki warns of a 'Greater Depression' coming to the US — with millions of Americans going poor. But he says these 2 'easy-money' assets will bring in 'great wealth'. How to get in now This is how American car dealers use the '4-square method' to make big profits off you — and how you can ensure you pay a fair price for all your vehicle costs Like what you read? Join 200,000+ readers and get the best of Moneywise straight to your inbox every week. This article provides information only and should not be construed as advice. It is provided without warranty of any kind. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
